Please login to the form below

Not currently logged in
Email:
Password:

Some SkyePharma jobs saved after Swiss facility deal with Aenova

Staff retained in sub-letting contract for oral supplement

A handful of axed staff members at SkyePharma's R&D facility in Muttenz, Switzerland have managed to retain their roles after a deal with Aenova.

SkyePharma said 11 technical staff have been recruited by Aenova, with the oral supplement manufacturer sub-letting part of the Muttenz laboratories.

SkyePharma plans to reduce its staff of 101 in Muttenz by 20 per cent  to generate cost savings of £1.8m (2.6m Swiss francs) a year.

German-based Aenova said it will use the centre to expand its own oral product development activities as well as carrying out oral product formulation and analytical services for SkyePharma on a sub-contract basis.

The two companies already have a similar deal in place, with SkyePharma leasing its entire pharmaceutical manufacturing business and premises at Saint Quentin-Fallavier, Lyon, France, to Aenova.

The Lyon deal saw Aenova assume responsibility for 60 SkyePharma staff, with the company able to boost its market presence in France.

SkyePharma's CEO Peter Grant said he was pleased the deal had seen several Switzerland-based staff had been offered roles with Aenova.

He continued: “Through this further alliance we retain the capability to offer innovative oral drug delivery solutions, using the same staff on a sub-contract basis for laboratory work.

“Our Muttenz business will continue to operate competitively but with lower fixed costs, providing greater flexibility for our new business and R&D activities.”

Grant recently replaced Axel Muller as CEO, after Muller stepped down in January to “pursue other interests”.

SkyePharma said the changes at its Muttenz laboratories would not affect relationships with its customers, with the company looking to subcontract oral development and manufacturing to Aenova when appropriate.

10th February 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics